semaglutide trial adolescents obesity 2022 50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj Weight loss drug Wegovy helped

Trials have flagged some concerns not typical of Wegovy: increased heart rate, irregular heartbeats in 2-11% of participants, and dysesthesia

They should not be treated as interchangeable

GSH levels have been shown to decrease with ageing and in several age-related degenerative diseases and AD in particular (Harris et al., Whilst extracellular A plaques, NFT, inflammation in the form or reactive astrocytes and microglia, and neuronal loss are all consistent pathological features of AD, a mechanistic link between these factors is yet to be clarified

P = 0.004

Effectiveness loss Subjective but important : Results diminishing despite same dose No change in injury healing progression Reduced effectiveness compared to fresh vial This can indicate : Peptide losing potency over time